Krystal Biotech, Inc. (KRYS)

Krystal Biotech Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	204.83	89.16	10.93	-139.98	-69.57
Depreciation & Amortization	6.55	6.71	5.91	3.39	2.77
Stock-Based Compensation	54.51	49.13	39.93	33.23	15.32
Other Adjustments	-28.61	-7.12	-107.06	0.13	1.04
Change in Receivables	-22.12	-62.71	-42.04	-	-
Changes in Inventories	-6.29	-11.91	-4.48	-	-
Changes in Accounts Payable	0.83	1.01	-0.1	-1.25	0.71
Changes in Accrued Expenses	4.12	67.47	10.54	5.17	2.71
Changes in Other Operating Activities	-12.96	-8.32	-2.44	-1.26	-0.91
Operating Cash Flow	200.87	123.42	-88.8	-100.57	-47.94
Operating Cash Flow Growth	62.75%	-	-	-	-
Capital Expenditures	-11.95	-4.24	-11.8	-52.98	-68.34
Sale of Property, Plant & Equipment	-	0.44	-	-	-
Proceeds from Sale of Intangible Assets	-	-	100	-	-
Purchases of Investments	-422.54	-457.74	-508.78	-318.78	-190.46
Proceeds from Sale of Investments	375.64	298.54	503.21	257.68	32.03
Investing Cash Flow	-58.42	-163.44	82.64	-114.08	-226.77
Issuance of Common Stock	22.66	32.4	203.5	36	355.65
Repurchase of Common Stock	-13.96	-5.39	-0.75	-0.65	-
Net Common Stock Issued (Repurchased)	8.71	27.01	202.75	35.35	355.65
Other Financing Activities	-	-	-	-	-7.96
Financing Cash Flow	8.71	27.01	202.75	35.35	347.69
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.29	-0.46	-0.16	-0.04	-
Net Cash Flow	151.44	-13.46	196.43	-179.35	72.98
Free Cash Flow	188.91	119.18	-100.6	-153.55	-116.27
Free Cash Flow Growth	58.51%	-	-	-	-
FCF Margin	48.55%	41.02%	-198.43%	-	-
Free Cash Flow Per Share	6.31	4.01	-3.63	-6.02	-5.24
Levered Free Cash Flow	185.14	139.88	8.56	-186.91	-132.63
Unlevered Free Cash Flow	154.68	112.2	-95.29	-192.13	-131.34

Updated Feb 17, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q